{"id":"chidamide","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":["Epidaza","HDACi Chidamide","CS055","HBI-8000","HDACi"],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T13:45:25.806235","offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Nicotinamide phosphoribosyltransferase, Histone deacetylase 1, Histone deacetylase 10","modality":"Small Molecule"},"_scrapedAt":"2026-03-28T01:05:37.092Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Peripheral T-cell lymphoma","diseaseId":"peripheral-t-cell-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Relapsed or refractory T-cell leukemia-lymphoma","diseaseId":"relapsed-or-refractory-t-cell-leukemia-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["modality→Small Molecule"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07493330","phase":"PHASE1, PHASE2","title":"Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-03-23","conditions":"PTCL, Refractory","enrollment":86},{"nctId":"NCT07493148","phase":"PHASE2","title":"Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-04-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":50},{"nctId":"NCT07493109","phase":"PHASE3","title":"Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-05-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":200},{"nctId":"NCT04661943","phase":"PHASE2","title":"Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Ou Bai, MD/PHD","startDate":"2017-06-01","conditions":"Diffuse Large B-cell Lymphoma","enrollment":30},{"nctId":"NCT07489989","phase":"PHASE2","title":"Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.","status":"RECRUITING","sponsor":"Daihong Liu","startDate":"2025-05-15","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)","enrollment":30},{"nctId":"NCT07320963","phase":"PHASE1, PHASE2","title":"Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-31","conditions":"Nasopharyngeal Carcinoma","enrollment":52},{"nctId":"NCT07380984","phase":"PHASE2","title":"PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-03","conditions":"Natural Killer/T-cell Lymphoma","enrollment":47},{"nctId":"NCT06928376","phase":"PHASE2","title":"A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-04-18","conditions":"Acute Myeloid Leukemia, First Line Therapy","enrollment":160},{"nctId":"NCT05029141","phase":"PHASE2","title":"New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-09-01","conditions":"Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML","enrollment":21},{"nctId":"NCT06220162","phase":"PHASE2","title":"VAC Regimen for AML Patients Who Failed to Response to VA Regimen","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-02-01","conditions":"Acute Myeloid Leukemia","enrollment":32},{"nctId":"NCT06497985","phase":"PHASE3","title":"A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients","status":"RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2024-12-06","conditions":"Colorectal Cancer","enrollment":430},{"nctId":"NCT04651127","phase":"PHASE1, PHASE2","title":"Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2020-11-09","conditions":"Cervical Cancer, Cervix Cancer, Cervix Neoplasm","enrollment":5},{"nctId":"NCT07412262","phase":"PHASE2","title":"A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer With Acquired Resistance to Immunotherapy and High YAP Protein Expression","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2026-03-31","conditions":"Non-Small Cell Lung Cancer","enrollment":32},{"nctId":"NCT07415980","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-04-01","conditions":"Double Expressor DLBCL","enrollment":68},{"nctId":"NCT07397832","phase":"PHASE2","title":"CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-01-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":58},{"nctId":"NCT07373964","phase":"PHASE2","title":"A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)","status":"RECRUITING","sponsor":"China Medical University, China","startDate":"2025-10-15","conditions":"Small Cell Lung Cancer","enrollment":36},{"nctId":"NCT06951997","phase":"PHASE2","title":"QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-03-07","conditions":"Metastatic Pancreatic Cancer","enrollment":33},{"nctId":"NCT06068621","phase":"PHASE2","title":"Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2023-03-01","conditions":"Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT07339527","phase":"PHASE1, PHASE2","title":"EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-01","conditions":"Mature T-cell and NK-cell Lymphoma","enrollment":60},{"nctId":"NCT06776952","phase":"PHASE3","title":"A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Evopoint Biosciences Inc.","startDate":"2025-04-10","conditions":"Relapsed/Refractory Peripheral T Cell Lymphoma","enrollment":120},{"nctId":"NCT06122389","phase":"PHASE3","title":"SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-02-05","conditions":"Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy","enrollment":130},{"nctId":"NCT07318831","phase":"PHASE2","title":"Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-31","conditions":"Neuroblastoma (NB), Neuroblastoma in Children","enrollment":27},{"nctId":"NCT06393361","phase":"PHASE2","title":"Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-06-01","conditions":"Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma","enrollment":100},{"nctId":"NCT07093710","phase":"PHASE1, PHASE2","title":"Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-27","conditions":"Peripheral T Cell Lymphoma","enrollment":101},{"nctId":"NCT07304232","phase":"PHASE2","title":"Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-09-01","conditions":"Allogeneic Hematopoietic Cell Transplantation (HCT), AML (Acute Myeloid Leukemia)","enrollment":134},{"nctId":"NCT05141357","phase":"PHASE2","title":"A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"HUYABIO International, LLC.","startDate":"2022-02-15","conditions":"Non Small Cell Lung Cancer","enrollment":5},{"nctId":"NCT06584227","phase":"PHASE2","title":"Adebrelimab and Chidamide for Pancreatic Cancer","status":"RECRUITING","sponsor":"Liu Xiufeng","startDate":"2024-09-10","conditions":"Pancreatic Cancer, Adult","enrollment":45},{"nctId":"NCT06421948","phase":"PHASE1, PHASE2","title":"Linperlisib Combined With Chidamide in Patients With PTCL","status":"RECRUITING","sponsor":"Yanyan Liu","startDate":"2024-05-25","conditions":"Peripheral T-cell Lymphoma","enrollment":134},{"nctId":"NCT05991973","phase":"PHASE2","title":"Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2023-07-15","conditions":"T Lymphoblastic Leukemia/Lymphoma","enrollment":44},{"nctId":"NCT05083208","phase":"PHASE1","title":"PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma","status":"TERMINATED","sponsor":"Henan Cancer Hospital","startDate":"2022-02-20","conditions":"Peripheral T-Cell Lymphoma","enrollment":12},{"nctId":"NCT05566054","phase":"PHASE2","title":"Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-03-01","conditions":"Acute Monocytic Leukemia, Newly Diagnosed","enrollment":92},{"nctId":"NCT06532552","phase":"PHASE2","title":"Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-07-29","conditions":"Acute Myeloid Leukemia, Adult, Newly Diagnosed","enrollment":172},{"nctId":"NCT07234162","phase":"PHASE3","title":"A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)","status":"RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2024-05-13","conditions":"Peripheral T-cell Lymphoma","enrollment":218},{"nctId":"NCT06451861","phase":"PHASE2","title":"Randomized Study of ABC-14 Regimen Compared With \"3+7\" Standard Induction Therapy or AB-14 for ND AML","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-08-21","conditions":"Acute Myeloid Leukemia","enrollment":240},{"nctId":"NCT05270200","phase":"PHASE1, PHASE2","title":"Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse","status":"RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2022-02-01","conditions":"Leukemia, Myeloid, Acute","enrollment":20},{"nctId":"NCT06947967","phase":"PHASE3","title":"Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","status":"RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2025-08-12","conditions":"Lymphoma, T-Cell, Peripheral","enrollment":224},{"nctId":"NCT05305859","phase":"PHASE2","title":"Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2022-01-12","conditions":"Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia","enrollment":30},{"nctId":"NCT07168317","phase":"PHASE2","title":"Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL","status":"RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2025-08-01","conditions":"New Diagnosed Angioimmunoblastic T-Cell Lymphoma","enrollment":40},{"nctId":"NCT07159620","phase":"PHASE2","title":"Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-01","conditions":"Adult T-cell Leukemia/Lymphoma","enrollment":27},{"nctId":"NCT03838354","phase":"PHASE1, PHASE2","title":"A Clinical Trial of Chidamide in the Management of Refractory ITP","status":"COMPLETED","sponsor":"Shandong University","startDate":"2021-06-01","conditions":"Thrombocytopenia","enrollment":61},{"nctId":"NCT07139353","phase":"PHASE1, PHASE2","title":"Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-15","conditions":"Peripheral T Cells Lymphoma (PTCL)","enrollment":54},{"nctId":"NCT07133763","phase":"PHASE1, PHASE2","title":"Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders.","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2025-09-01","conditions":"EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor, Tenofovir","enrollment":50},{"nctId":"NCT07133776","phase":"PHASE1, PHASE2","title":"Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2025-09-01","conditions":"Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor, Tenofovir","enrollment":30},{"nctId":"NCT06556862","phase":"PHASE2","title":"Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor","status":"NOT_YET_RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-10-01","conditions":"HR+/HER2- Advanced Breast Cancer","enrollment":155},{"nctId":"NCT07105631","phase":"","title":"Patient-reported Outcomes (PRO) and Treatment Outcomes of Chinese Patients With MSS-type Advanced Colorectal Cancer Who Received the Zidovudine Combination Regimen in the Real World","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-07-10","conditions":"Colorectal Cancer","enrollment":300},{"nctId":"NCT06386302","phase":"NA","title":"Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-08-05","conditions":"AML, Acute Myeloid Leukemia","enrollment":184},{"nctId":"NCT07081607","phase":"PHASE2","title":"Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-07-15","conditions":"Peripheral T-Cell Lymphoma, Not Classified","enrollment":30},{"nctId":"NCT05632848","phase":"PHASE2","title":"Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2022-06-15","conditions":"Triple Negative Breast Cancer","enrollment":47},{"nctId":"NCT07074457","phase":"NA","title":"Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-11-01","conditions":"CD30+ Peripheral T-cell Lymphoma","enrollment":47},{"nctId":"NCT07072221","phase":"NA","title":"Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-11-01","conditions":"Peripheral T-cell Lymphoma","enrollment":40},{"nctId":"NCT07058103","phase":"PHASE2","title":"Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL","status":"RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2025-04-01","conditions":"Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory","enrollment":40},{"nctId":"NCT04668690","phase":"PHASE3","title":"Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-04-13","conditions":"Peripheral T Cell Lymphoma","enrollment":193},{"nctId":"NCT03031262","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Chidamide in CBF Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2017-02-08","conditions":"AML","enrollment":250},{"nctId":"NCT06979908","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2025-01-22","conditions":"Metastatic Colorectal Cancer","enrollment":46},{"nctId":"NCT06930118","phase":"PHASE2","title":"The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2025-04-10","conditions":"Advanced Colorectal Cancer in the Third-line Treatment and Beyond, pMMR/MSS Advanced Colorectal Cancer","enrollment":60},{"nctId":"NCT06902038","phase":"NA","title":"Clinical Research on the Use of Immune Checkpoint Inhibitors Combined With Chidamide for the Functional Cure of AIDS","status":"NOT_YET_RECRUITING","sponsor":"Jun Chen, MD","startDate":"2025-03-22","conditions":"HIV-1 Infection","enrollment":33},{"nctId":"NCT06890585","phase":"PHASE2","title":"Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Li Zhiming","startDate":"2025-06-01","conditions":"BTK Inhibitors, Histone Deacetylase Inhibitor, Double Express Diffuse Large B-cell Lymphoma","enrollment":128},{"nctId":"NCT06891157","phase":"PHASE2","title":"Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-08-20","conditions":"Chidamide, R-CHOP Chemotherapy, DLBCL - Diffuse Large B Cell Lymphoma","enrollment":148},{"nctId":"NCT06764017","phase":"PHASE2","title":"CHiR Therapy for Elderly DLBCL Intolerant to Chemo","status":"RECRUITING","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-02-01","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":30},{"nctId":"NCT06758037","phase":"PHASE2","title":"Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to Chemotherapy","status":"RECRUITING","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-01-15","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":50},{"nctId":"NCT06570447","phase":"PHASE2","title":"Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-05-15","conditions":"Diffuse Large B-Cell Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Refractory","enrollment":22},{"nctId":"NCT05770882","phase":"PHASE1, PHASE2","title":"Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)","status":"TERMINATED","sponsor":"Great Novel Therapeutics Biotech & Medicals Corporation","startDate":"2023-04-25","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":7},{"nctId":"NCT05833724","phase":"PHASE2","title":"Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)","status":"RECRUITING","sponsor":"Great Novel Therapeutics Biotech & Medicals Corporation","startDate":"2024-10-18","conditions":"Relapsed or Refractory Peripheral T-cell Lymphoma","enrollment":33},{"nctId":"NCT06858956","phase":"","title":"Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-03-01","conditions":"Colorectal Cancer","enrollment":200},{"nctId":"NCT06858969","phase":"PHASE2","title":"Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-04-09","conditions":"Metastatic Colorectal Cancer","enrollment":130},{"nctId":"NCT06151106","phase":"PHASE2","title":"Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2023-11-22","conditions":"Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma","enrollment":33},{"nctId":"NCT05603884","phase":"PHASE2","title":"VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2022-12-01","conditions":"Leukemia, Myeloid, Acute, AML Stage, Adult","enrollment":66},{"nctId":"NCT06779435","phase":"","title":"A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-01-01","conditions":"DLBCL","enrollment":400},{"nctId":"NCT06158386","phase":"PHASE2","title":"Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2023-11-22","conditions":"Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma","enrollment":33},{"nctId":"NCT05881265","phase":"PHASE2","title":"Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-05-15","conditions":"APL","enrollment":30},{"nctId":"NCT06757387","phase":"PHASE1, PHASE2","title":"Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-12-30","conditions":"Peripheral T-cell Lymphoma","enrollment":45},{"nctId":"NCT05958719","phase":"PHASE2","title":"Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-03-02","conditions":"Peripheral T Cell Lymphoma, Epigenetic Repression","enrollment":37},{"nctId":"NCT06701357","phase":"PHASE2","title":"CR-CHOP+X in Previously Untreated DEL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-10","conditions":"DLBCL","enrollment":49},{"nctId":"NCT06750848","phase":"PHASE2","title":"Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jundong Wu","startDate":"2024-12-20","conditions":"Advanced Breast Cancer","enrollment":48},{"nctId":"NCT06750991","phase":"PHASE2","title":"CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p)","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-31","conditions":"DLBCL","enrollment":34},{"nctId":"NCT06748521","phase":"PHASE2","title":"Dynamic CtDNA-guided Targeted Therapy in DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-31","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":108},{"nctId":"NCT06745193","phase":"PHASE2","title":"A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2025-02-01","conditions":"Advanced Esophageal Carcinoma","enrollment":63},{"nctId":"NCT05281276","phase":"PHASE1","title":"Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)","status":"TERMINATED","sponsor":"Taipei Medical University Shuang Ho Hospital","startDate":"2022-09-20","conditions":"Metastatic Colorectal Cancer","enrollment":9},{"nctId":"NCT06739395","phase":"PHASE2","title":"Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2024-11-01","conditions":"Solid Tumor, Precision Medicine","enrollment":300},{"nctId":"NCT04231448","phase":"PHASE3","title":"Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2020-05-21","conditions":"Diffuse Large B-cell Lymphoma","enrollment":423},{"nctId":"NCT04562311","phase":"PHASE2","title":"Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-01-01","conditions":"Bladder Cancer Stage IV","enrollment":45},{"nctId":"NCT06709885","phase":"PHASE2","title":"HDAC Inhibitor Combination with Chemoimmunotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon Cancer","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2024-10-15","conditions":"Colon Adenocarcinoma","enrollment":100},{"nctId":"NCT06685276","phase":"PHASE2","title":"Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Dai, Guanghai","startDate":"2024-08-16","conditions":"Colorectal Cancer Metastatic","enrollment":46},{"nctId":"NCT06674096","phase":"PHASE2","title":"RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-11-06","conditions":"Double-expressor Lymphoma","enrollment":44},{"nctId":"NCT06682247","phase":"","title":"A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Feng Wang","startDate":"2024-11-15","conditions":"Colorectal Cancer Metastatic","enrollment":200},{"nctId":"NCT04512534","phase":"PHASE2","title":"Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2020-11-13","conditions":"Peripheral T-cell Lymphoma","enrollment":51},{"nctId":"NCT05659992","phase":"PHASE2","title":"Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2022-12-25","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT06671717","phase":"NA","title":"Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-12","conditions":"Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma","enrollment":25},{"nctId":"NCT05348213","phase":"PHASE2","title":"Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2022-05-16","conditions":"Diffuse Large B Cell Lymphoma","enrollment":76},{"nctId":"NCT06652152","phase":"","title":"Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-10-30","conditions":"Diffuse Large B Cell Lymphoma (DLBCL), Double Expressor Lymphoma","enrollment":400},{"nctId":"NCT06637007","phase":"PHASE2","title":"Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Shanxi Province Cancer Hospital","startDate":"2024-08-01","conditions":"Sarcoma,Soft Tissue, Sarcoma, Sarcoma of Bone","enrollment":30},{"nctId":"NCT06550336","phase":"PHASE2","title":"A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL).","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2024-06-30","conditions":"Peripheral T Cell Lymphoma","enrollment":35},{"nctId":"NCT06563778","phase":"PHASE2","title":"Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-09-01","conditions":"Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma","enrollment":100},{"nctId":"NCT06547476","phase":"PHASE2","title":"Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-09-01","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT05519865","phase":"PHASE2","title":"A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2022-10-26","conditions":"Non Small Cell Lung Cancer","enrollment":118},{"nctId":"NCT05068427","phase":"PHASE2","title":"Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.","status":"COMPLETED","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2021-11-23","conditions":"Non Small Cell Lung Cancer","enrollment":34},{"nctId":"NCT06516978","phase":"PHASE2","title":"A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-10-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":528},{"nctId":"NCT06492629","phase":"PHASE2","title":"Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-04-03","conditions":"PTCL","enrollment":43},{"nctId":"NCT06408623","phase":"PHASE2","title":"Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-05-15","conditions":"Liver Cancer","enrollment":48},{"nctId":"NCT05075460","phase":"PHASE3","title":"Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-10-01","conditions":"T-cell Lymphoma","enrollment":107}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"PYREXIA"},{"count":5,"reaction":"BONE MARROW FAILURE"},{"count":3,"reaction":"ANAEMIA"},{"count":3,"reaction":"DIARRHOEA"},{"count":3,"reaction":"FATIGUE"},{"count":3,"reaction":"NAUSEA"},{"count":3,"reaction":"PNEUMONITIS"},{"count":2,"reaction":"ACUTE KIDNEY INJURY"},{"count":2,"reaction":"ARTHRALGIA"},{"count":2,"reaction":"BLOOD URIC ACID INCREASED"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":442,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_3","status":"active","brandName":"Chidamide","genericName":"Chidamide","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Chidamide is a small molecule histone deacetylase inhibitor (HDI) that targets Class I and Class IIb histone deacetylases. It is being studied in clinical trials for various conditions, including Peripheral T-Cell Lymphoma, Metastatic Colorectal Cancer, and others, often in combination with other treatments.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":59,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}